Movesan Pregnancy

• Pregnancy of Movesan in details
• Movesan breastfeeding
• Movesan reviews

Pregnancy of Movesan in details

Animal reproduction studies in mice, rats, and rabbits revealed evidence of teratogenicity, such as increased fetal malformations and decreased fetal growth (measured by lower fetal weights and/or delayed ossification). Dystocia and related complications were also observed when administered in late gestation. In mice, subcutaneous administration produced cleft palate at approximately one-third of the maximum recommended daily human dose (MRHD). In rats, topical administration produced umbilical hernia at doses approximately 6 times the MRHD. Subcutaneous administration in rats, throughout pregnancy or late in gestation, had caused prolonged and difficult labor, fewer live births, lower birth weight, and reduced early pup survival at doses approximately 8 times the MRHD. In rabbits, topical administration caused multiple malformations (e.g., flexed front paws, gallbladder agenesis, umbilical hernia, hydrocephaly) at doses approximately 3 times the MRHD. There are no adequate and well-controlled studies in pregnant women. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

This drug should not be used during pregnancy unless the benefit outweighs the risk to the fetus. US FDA pregnancy category: C Comments: -Hypoadrenalism may occur in infants born to women receiving corticosteroids during pregnancy. -Monitor signs of hypoadrenalism in infants born to mothers taking substantial corticosteroid doses during pregnancy.

Movesan breastfeeding

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother. Excreted into human milk: Unknown Excreted into animal milk: Data not available Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
2. "Product Information. Asmanex HFA (Movesan)." Merck & Company Inc, Whitehouse Station, NJ.
3. "Product Information. Asmanex Twisthaler (Movesan)." Schering-Plough Corporation, Kenilworth, NJ.

References for breastfeeding information

1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
2. "Product Information. Asmanex Twisthaler (Movesan)." Schering-Plough Corporation, Kenilworth, NJ.
3. "Product Information. Asmanex HFA (Movesan)." Merck & Company Inc, Whitehouse Station, NJ.

References

1. DailyMed. "FORMOTEROL FUMARATE; MOMETASONE FUROATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
2. PubMed Health. "Nasonex: This section provide the link out information of drugs collectetd in PubMed Health. ". http://www.ncbi.nlm.nih.gov/pubmedhe... (accessed September 17, 2018).

Reviews

Consumer reviews

Information checked by Dr. Sachin Kumar, MD Pharmacology